Pembrolizumab for Gastroesophageal Junction Cancer

"Yes, the data posted on clinicaltrials.gov confirms that recruitment for this study is ongoing. This medical trial was originally published on August 10th 2020 and recently updated in late August 2022. The current goal is to recruit 24 patients from 7 different sites."

"There is limited clinical data demonstrating the safety of Pembrolizumab, resulting in a rating of 2. No data exists yet to prove its efficacy."

"Presently, this study is being conducted at 7 different sites situated in Commack, Montvale and Uniondale as well as 4 other places. It may be advantageous to choose the closest clinic so that your attending-related travel costs are minimized if you participate."

"Affirmative. According to the clinicaltrials.gov registry, this medical research is actively seeking participants with a recruitment timeline beginning on August 10th 2020 and culminating in an update posted on August 29th 2022. In total, there are 24 slots available across 7 trial sites."

"Currently, 1139 clinical trials are underway to further research pembrolizumab and 170 of those studies have reached Phase 3. These investigations span 49616 medical sites with the majority being in Houston, Texas."

"Pembrolizumab is oft employed in the treatment of cancerous growths. It can also be effective for patients with unresectable melanoma, a high level of microsatellite instability, and those at risk for relapse."